JP7399693B2 - Tolerance inhibitor, food and drink composition for inhibiting tolerance, method for inhibiting tolerance - Google Patents

Description

The present invention relates to a resistance inhibitor that inhibits the resistance of antimicrobial-resistant bacteria to an antimicrobial drug, and in particular, a resistance inhibitor that inhibits the resistance to at least one of β-lactam antibiotics and aminoglycoside antibiotics. Regarding etc.

Staphylococcus aureus is a Gram-positive coccus and is a resident bacteria that exists on the skin and nasal cavities of humans and animals. Staphylococcus aureus normally does not cause any harm, but it is known to cause various diseases when the immune system is weakened. There are a variety of diseases caused by Staphylococcus aureus, from relatively mild diseases such as suppuration and food poisoning to serious diseases such as pneumonia, peritonitis, sepsis, and meningitis.

Antibacterial drugs (antibiotics) such as methicillin have been used to treat Staphylococcus aureus. However, as a result of the worldwide use of antibiotics such as methicillin, methicillin-resistant Staphylococcus aureus (hereinafter also referred to as "MRSA") that has acquired resistance to antibiotics has emerged. Recent studies have shown that MRSA is a multidrug-resistant bacteria that is resistant not only to β-lactam antibiotics such as methicillin, but also to aminoglycoside antibiotics and macrolide antibiotics. It has been reported that.

In the case of infection with such antimicrobial-resistant bacteria, it is difficult to provide effective treatment with the currently used antibacterial agents, and new treatments and therapeutic agents are needed to treat infections caused by antimicrobial-resistant bacteria. It is being considered (for example, Patent Document 1).

Red ginseng is a food produced by heating and drying the roots of Panax ginseng (Panax ginseng C.A. Meyer), a member of the Araliaceae family. It is distinguished from white ginseng, which is dried at room temperature (16th edition Japanese Pharmacopoeia, pp. 1488-1489). Red ginseng and red ginseng extracts have been reported to have nourishing and tonic effects and angiogenesis-promoting effects, and have attracted attention in recent years (for example, Patent Document 2 and Patent Document 3).

Japanese Patent Application Publication No. 10-182655 Japanese Patent Application Publication No. 2004-155778 Japanese Patent Application Publication No. 2007-320970

As mentioned above, it has been reported that red ginseng and red ginseng extracts have nourishing and tonic effects and angiogenesis-promoting effects. However, it has not yet been reported that red ginseng extract can inhibit the resistance of antimicrobial-resistant bacteria to antimicrobial drugs.

An object of the present invention is to provide a resistance inhibitor that inhibits the resistance of antibiotic-resistant bacteria to at least one of β-lactam antibiotics and aminoglycoside antibiotics.

The present inventors have demonstrated that red ginseng extract inhibits the resistance of antibiotic-resistant bacteria to β-lactam antibiotics and aminoglycoside antibiotics, and that these antibiotics act effectively against antibiotic-resistant bacteria. The present invention was completed based on the discovery that the present invention can be easily carried out.

That is, the gist of the present invention is as follows.
[1] An inhibitor of resistance of antimicrobial-resistant bacteria to the antimicrobial agent, which contains red ginseng extract, and wherein the antimicrobial agent is at least one of a β-lactam antibacterial agent and an aminoglycoside antibacterial agent. A resistance inhibitor characterized by:
[2] The resistance inhibitor according to [1], wherein the red ginseng extract is an extract extracted using methanol.
[3] The resistance inhibitor according to [1] or [2], wherein the antibacterial agent is at least one of gentamicin and kanamycin.
[4] The resistance inhibitor according to any one of [1] to [3], wherein the antimicrobial agent-resistant bacterium is methicillin-resistant Staphylococcus aureus.
[5] A food and drink composition for inhibiting the resistance of antimicrobial-resistant bacteria to the antimicrobial agent, which contains an extract of red ginseng, and wherein the antimicrobial agent is at least one of a β-lactam antibacterial agent and an aminoglycoside antibacterial agent. A food/beverage composition for inhibiting tolerance characterized by being one of the above.
[6] A resistance inhibition method for inhibiting the resistance of antimicrobial-resistant bacteria to the antimicrobial agent, the method comprising ingesting a red ginseng extract, wherein the antimicrobial agent is a β-lactam antibacterial agent and an aminoglycoside antibacterial agent. A method of inhibiting resistance to at least one of the drugs.

According to the present invention, it is possible to provide a resistance inhibitor that inhibits the resistance of antibiotic-resistant bacteria to at least one of β-lactam antibiotics and aminoglycoside antibiotics.

Embodiments of the present invention will be described below.

The resistance inhibitor of the present embodiment (hereinafter also simply referred to as "inhibitor") includes an extract of red ginseng (hereinafter also simply referred to as "red ginseng extract"). Red ginseng is a food produced by heating and drying the root of Panax ginseng (Panax ginseng C.A. Meyer), a member of the Araliaceae family, and is defined in, for example, the 16th edition of the Japanese Pharmacopoeia, pages 1488-1489. Red ginseng can be used. The red ginseng used to obtain the red ginseng extract may be a powder, a cut product, or a crushed product.

The method for obtaining the red ginseng extract is not particularly limited, but for example, a dipping method can be used to obtain the extract (red ginseng extract) by immersing the extraction target (red ginseng) in a solvent. . Examples of the solvent used in the immersion method include alcohol (methanol, ethanol, etc.) and water.

From the viewpoint of easily inhibiting the resistance of antibiotic-resistant bacteria to at least one of β-lactam antibiotics and aminoglycoside antibiotics (hereinafter also simply referred to as "antibiotics"), red ginseng and methanol It is preferable to obtain a red ginseng extract by extraction with a solvent containing methanol, and more preferably to obtain a red ginseng extract by extraction with a solvent containing 60% by volume or more of methanol based on 100% by volume of the solvent.

Note that after extracting red ginseng with a solvent, the red ginseng extract may be purified. For example, an ODS column (OctaDecylSilyl column) can be used for the purification process. When a red ginseng extract extracted with a solvent containing methanol is purified, the saponin content of the red ginseng extract after the purification treatment is, for example, lower than that of the red ginseng extract (the solvent is The content of components other than saponin contained in red ginseng is 90% by mass or more (relative to 100% by mass of the red ginseng extract in the state in which the solvent has been removed), and the content of components other than saponin in red ginseng is 10% by mass or less (based on 100% by mass of red ginseng extract). Here, components other than saponin contained in red ginseng include carbohydrates (polysaccharides, monosaccharides, disaccharides, trisaccharides, fiber, pectin) and nitrogen compounds (proteins, amino acids, peptides, nucleic acids, alkaloids). They include fat-soluble components (lipids, fatty acids, essential oils, plant sterols, organic acids, phenolic compounds, polyacetylene compounds, terpenoids), and vitamins (water-soluble vitamins).

The red ginseng extract may be a solid (powder) from which the solvent has been removed, or a liquid from which the solvent remains. Note that the solid (powder) red ginseng extract from which the solvent has been removed is dissolved and/or dispersed in a pharmacologically acceptable dispersion medium (e.g., water), and the liquid is used as the inhibitor of this embodiment. May be used.

The specific conditions for the immersion method are not particularly limited, but from the viewpoint of easily inhibiting the resistance of antimicrobial-resistant bacteria to antimicrobial drugs (β-lactam antibacterial drugs and/or aminoglycoside antibacterial drugs), The temperature of the solvent in which the red ginseng is soaked is preferably 40 to 90°C, more preferably 60 to 90°C. Further, for example, the time for immersing the red ginseng in the solvent can be 4 to 48 hours.

Here, in order to obtain the red ginseng extract, it is preferable to use reflux extraction among the immersion methods. Reflux extraction is an extraction method in which red ginseng is immersed in a solvent and extracted by heating, while the evaporated solvent and volatile components are cooled and condensed and returned to the solvent in which the red ginseng is immersed. In addition, when performing reflux extraction under pressure, the extraction can be performed at a low temperature (for example, 10 to 40°C) and for a short time (for example, several tens of minutes to 4 hours).

The content of the red ginseng extract contained in the inhibitor of the present embodiment is not particularly limited, and can be appropriately set in consideration of the form (dosage form), intake amount, etc. described later.

The inhibitor of this embodiment may be composed only of the red ginseng extract, or may contain other components other than the red ginseng extract. Other ingredients include pharmacologically acceptable carriers, excipients, integrators, preservatives, stabilizers, flavorings, pH adjusters, dispersion media, and ingredients contained in foods and drinks (hereinafter referred to as ``foods and beverages''). (also referred to as "components"), components contained in feed, etc.

The form (dosage form) of the inhibitor of this embodiment is not particularly limited, but it is preferably in the form of internal use such as plain tablets, sugar-coated tablets, granules, powders, liquids, tablets, and capsules (hard capsules, soft capsules). Note that the method of ingesting the inhibitor of this embodiment can be appropriately set depending on the form (dosage form), etc., and is not particularly limited, but for example, it can be ingested orally. In addition, when the inhibitor of this embodiment is used as a food or drink, the inhibitor of this embodiment may contain a food or drink ingredient, such as a beverage (such as a soft drink such as coffee, juice, or tea drink, a milk drink, or a lactic acid bacteria drink). , yogurt drinks, carbonated drinks, etc.), confectionery (chocolate, donuts, pies, cream puffs, gum, jelly, candy, cookies, cakes, puddings, daifuku, mochi, manju, castella, anmitsu, yokan, etc.), seasonings ( It can also be used as dressing, furikake, umami seasoning, soup base, etc.).

The inhibitor of this embodiment can be used as a medicine, a quasi-drug, and a food or drink. When the inhibitor of this embodiment is used as a food or drink, it may be a normal food or drink, but it is preferably a health food, a food with functional claims, a nutritional supplement, a supplement, or a food for specified health uses. Note that the method for producing the inhibitor of this embodiment is not particularly limited, and can be formulated by a known method depending on the type of drug, quasi-drug, food or drink, etc.

The person who ingests the inhibitor of this embodiment includes humans and animals other than humans. Examples of non-human animals include higher vertebrates other than humans, especially mammals other than humans, and more specifically, pet animals such as dogs and cats, and livestock such as cows, horses, pigs, and sheep. can do. Further, the ingester may be a carrier of antimicrobial-resistant bacteria or a non-carrier of antimicrobial-resistant bacteria.

According to the inhibitor of this embodiment, the resistance (hereinafter also simply referred to as "resistance") of antibacterial drug-resistant bacteria to antibacterial drugs can be inhibited. Here, inhibiting resistance to antibacterial drugs means that by ingesting the inhibitor of this embodiment, the antibacterial drug becomes more effective with a smaller amount than when not ingesting the inhibitor of this embodiment. , refers to lowering resistance to antibiotics. Therefore, if a carrier of antimicrobial-resistant bacteria ingests the inhibitor of this embodiment, the resistance of antimicrobial-resistant bacteria to antimicrobial agents will be suppressed, and the antimicrobial agent will more easily act on antimicrobial-resistant bacteria. On the other hand, if a non-carrier who does not carry antimicrobial-resistant bacteria ingests the inhibitor of this embodiment, the resistance of antimicrobial-resistant bacteria to antimicrobial drugs will be suppressed when the antimicrobial-resistant bacteria are carried. be able to. As a result, antibiotics are more likely to act on antibiotic-resistant bacteria. In addition, according to the inhibitor of the present embodiment, the resistance of antimicrobial-resistant bacteria to antibacterial drugs (β-lactam antibacterial drugs and/or aminoglycoside antibacterial drugs) can be improved, regardless of the type (strain) of antibacterial drug-resistant bacteria. can be inhibited.

Antibiotics that are more likely to act on antimicrobial-resistant bacteria are those to which antimicrobial-resistant bacteria are resistant, and specifically, at least one of β-lactam antibiotics and aminoglycoside antibiotics. It is an antibacterial agent.

Examples of β-lactam antibiotics include penicillin antibiotics such as penicillin, carbenicillin, oxacillin, ampicillin, and methicillin, cephem antibiotics such as cefoxitin and cefazolin, carbapenem antibiotics such as doripenem, and faropenem. Examples include penem antibiotics, monobactam antibiotics such as aztreonem, and combination drugs with β-lactamase inhibitors such as tazobactam/piperacillin (TAZ/PIPC).

Examples of aminoglycoside antibiotics include kanamycin, tobramycin, gentamicin, arbekacin, amikacin, streptomycin, dibekacin, bekanamycin, isepamycin, fradiomycin, ribostamycin, and neomycin.

Among the two types of antibacterial drugs mentioned above, the inhibitor of this embodiment tends to inhibit resistance to aminoglycoside antibacterial drugs. Furthermore, among aminoglycoside antibacterial drugs, the inhibitor of this embodiment tends to inhibit resistance to gentamicin and/or kanamycin. Therefore, the inhibitor of this embodiment is preferably used as an inhibitor that inhibits resistance to gentamicin and/or kanamycin.

Antibiotic-resistant bacteria whose resistance is inhibited by the inhibitor of the present embodiment are bacteria that have acquired resistance (tolerance) to at least one of β-lactam antibiotics and aminoglycoside antibiotics, In addition to these antibiotics, bacteria that have acquired resistance to other antibiotics may also be used. Specific examples of antimicrobial-resistant bacteria include methicillin-resistant Staphylococcus aureus (MRSA). In this specification, methicillin-resistant Staphylococcus aureus (MRSA) refers to both Staphylococcus aureus that is resistant only to methicillin and Staphylococcus aureus that is resistant to multiple types of antibiotics including methicillin. refers to

One aspect of the inhibitor of the present embodiment includes a food/beverage composition for inhibiting tolerance containing a red ginseng extract and a food/drink component. The food and drink composition for inhibiting tolerance may be a normal food or drink, but may also be a health food, a food with functional claims, a nutritional supplement, a supplement, a food for specified health use, or the like. This food/drink composition for inhibiting resistance can also inhibit the resistance of antimicrobial-resistant bacteria to antimicrobial agents, similarly to the inhibitor of the present embodiment.

Furthermore, the inhibitor of this embodiment can be used as an antibacterial agent for resistant bacteria in combination with the above-mentioned antibacterial agent (β-lactam antibacterial agent and/or aminoglycoside antibacterial agent). An antibacterial agent for resistant bacteria can inhibit resistance to an antibacterial agent by using an inhibitor, and can also kill antibacterial resistant bacteria whose resistance has been inhibited by the antibacterial agent (or can suppress the growth of antibacterial resistant bacteria). Antibacterial agents for resistant bacteria can be used as pharmaceuticals, for example, and may be in the form of a kit formulation in which the inhibitor and antibacterial agent are formulated separately, or in the form of a kit formulation in which the inhibitor and antibacterial agent are contained in one drug. It may also be a formulated preparation. Note that the antibacterial agent for resistant bacteria may contain other components described above in addition to the inhibitor and antibacterial agent of this embodiment.

The antibacterial agent for resistant bacteria preferably contains gentamicin and/or kanamycin and red ginseng extract. Red ginseng extract tends to inhibit the resistance of antimicrobial-resistant bacteria to gentamicin and kanamycin, so antibacterial agents for resistant bacteria should contain red ginseng extract and at least one of gentamicin and kanamycin. is preferred.

Next, the present invention will be described in more detail with reference to Examples. However, the present invention is not limited only to these examples.

A certain amount of red ginseng produced by heating (steaming) the root of Panax ginseng, which belongs to the Araliaceae family, and then drying it, is refluxed at 60 to 90°C for 3 to 5 hours in about 10 times the volume of 60 to 100% methanol by volume. Extracted. This was repeated five times, and all the extracted methanol solutions were combined and concentrated under reduced pressure using an evaporator to obtain a methanol extract. A certain amount of purified water was added to this methanol extract to dissolve it, an equal amount of n-butanol was added, the n-butanol was separated by two-phase partitioning, and the mixture was concentrated using an evaporator to obtain a dry powder. Next, this dry powder was dissolved in a small amount of methanol, 10 to 20 times the amount of ether or chloroform was added, and the fractions insoluble in these solvents were concentrated under reduced pressure to form a dry powder. Furthermore, the obtained dry powder was dissolved in 3 to 5 times the amount of purified water, added and adsorbed to an ODS (C18) column using purified water as the mobile phase, and first eluted with 2 to 3 times the amount of purified water as the carrier amount. , followed by elution with the same amount of 20% methanol by volume. Thereafter, it was eluted with 100 volume % methanol, which was about 5 times the amount of the carrier, and the methanol solution was concentrated under reduced pressure, and then freeze-dried to obtain a red ginseng extract (powder).

(Rating 1)
MRSA is resistant to multiple types of antibiotics, including oxacillin (β-lactams (penicillins)), carbenicillin (β-lactams (penicillins)), kanamycin (aminoglycosides), and tetracyclines (tetracyclines). (Methicillin Resistant Staphylococcus aureus IID1677 (Institute of Medical Science, The University of Tokyo)) was cultured overnight at 37°C in LB medium, and the turbidity (OD600 nm value) was 0.005 (5/3 × 10 ⁶ ) in Brain Heart Infusion (BHI) medium. A bacterial solution of CFU/mL (CFU: Colony Forming Unit, number of viable bacteria) was prepared. 90 μL of the bacterial solution was added to each well of a 96-well microplate so that the number of viable bacteria was 1.5×10 ⁵ CFU/well (CFU: Colony Forming Unit, number of viable bacteria). Furthermore, 5 μL/well of the following antibacterial agent and 5 μL/well of red ginseng extract (red ginseng extract was prepared at different concentrations by dissolving red ginseng extract (powder) in 10% methanol) were added. , and cultured at 37°C for 24 hours. After culturing, each well was visually inspected to determine the presence or absence of MRSA proliferation, and the minimum inhibitory concentration (MIC (μg/mL)) of the antimicrobial agent was determined. In addition, in order to determine detailed differences, 30 μL of bacterial solution and 30 μL of Bac-Titer Gro (manufactured by Promega) were mixed, and the amount of ATP in the bacteria was measured using a chemiluminescence method.

なお、抗菌薬を添加しない場合には、紅蔘抽出物を添加してもＭＲＳＡの生育（発育）に影響を及ぼすことはなかった。 The results are shown in Table 1.
[Table 1]

In addition, in the case where no antibacterial agent was added, even if red ginseng extract was added, the growth (development) of MRSA was not affected.

As shown in Table 1, when using β-lactam antibiotics or aminoglycoside antibiotics, even if red ginseng extract was added at 0.1 mg/mL, it was added at 1.0 mg/mL. Also, the MIC decreased compared to the case where red ginseng extract was not added. On the other hand, when a tetracycline antibiotic was used, such a decrease in MIC could not be confirmed even when red ginseng extract was added at a concentration of 0.1 mg/mL. Here, MIC refers to the minimum amount of antimicrobial agent that can inhibit the growth of bacteria. Therefore, a decrease in MIC means that the antibacterial agent becomes more effective. Therefore, from the results of this evaluation, it was understood that the inhibitor of this embodiment was able to inhibit the resistance of MRSA to at least one of β-lactam antibiotics and aminoglycoside antibiotics. .

Furthermore, regarding the MIC shown in Table 1, the MIC reduction rate expressed by the following formula (1) was calculated. The results are shown in Table 2 below.

[Table 2]

As shown in Table 2, when the concentration of red ginseng extract was 1.0 mg/mL, oxacillin and kanamycin had a greater MIC reduction rate than carbenicillin. From this result, it was understood that the inhibitor of the present embodiment inhibits the resistance of MRSA to kanamycin and oxacillin more easily than carbenicillin.

(Evaluation 2)
In this evaluation, the influence of red ginseng extract was evaluated using four different strains of MRSA. To evaluate the effect of red ginseng extract, use the same method as in evaluation 1 to measure the MIC when red ginseng extract is added and the MIC when red ginseng extract is not added, and compare these. So I went there. The amount of red ginseng extract added was 1.0 mg/mL using red ginseng extract (powder) dissolved in 10% methanol (the final concentration of methanol was 0.5). %), Red ginseng extract (powder) was adjusted to 5.0 mg/mL using red ginseng extract dissolved in 25% methanol (final concentration of methanol was 1.25%), Red ginseng extract (powder) ) was adjusted to 10.0 mg/mL using a red ginseng extract dissolved in 25% methanol (the final concentration of methanol was 1.25%). Here, the difference in methanol concentration did not affect the growth (development) of MRSA.

In this evaluation, in addition to MRSA IID1677 (Institute of Medical Science, The University of Tokyo) used in Evaluation 1, the four types of MRSA include MRSA ATCC BAA-1717 (American Type Culture Collection (ATCC)) and MRSA ATCC33592 (ATCC (American Type Culture Collection)). American Type Culture Collection)) and MRSA ATCC43300 (ATCC (American Type Culture Collection)) were used.

MRSA IID1677 (hereinafter also simply referred to as "IID1677") contains not only the antibiotics used in Evaluation 1 (oxacillin, carbenicillin, kanamycin, and tetracycline), but also ampicillin (β-lactam (penicillin)), cefazolin ( It was also confirmed that they were resistant to β-lactams (cephems), gentamicin (aminoglycosides), and erythromycin (macrolides). Therefore, in this evaluation using IID1677, MIC was measured using these antibacterial agents.

In addition, MRSA ATCC BAA-1717 (hereinafter simply referred to as "BAA-1717") is a drug that contains ampicillin (β-lactam type (penicillin type)), carbenicillin (β-lactam type (penicillin type)), and cefazolin (β-lactam type (penicillin type)). It was confirmed that the drug was resistant to lactams (cephems), kanamycin (aminoglycosides), gentamicin (aminoglycosides), and erythromycin (macrolides). Therefore, in this evaluation using BAA-1717, MIC was measured using these antibiotics.

In addition, MRSA ATCC 33592 (hereinafter also simply referred to as "ATCC 33592") is a type of ampicillin (β-lactam series (penicillin series)), oxacillin (β-lactam series (penicillin series)), carbenicillin (β-lactam series (penicillin series)), )), kanamycin (aminoglycoside), tetracycline (tetracycline), and erythromycin (macrolide). Therefore, in this evaluation using ATCC33592, MIC was measured using these antibiotics.

MRSA ATCC43300 (hereinafter also simply referred to as "ATCC43300") is a drug containing ampicillin (β-lactam type (penicillin type)), carbenicillin (β-lactam type (penicillin type)), kanamycin (aminoglycoside type), and erythromycin (macrolide). It was confirmed that it has resistance to Therefore, in this evaluation using ATCC43300, MIC was measured using these antibacterial agents.

なお、抗菌薬を添加しない場合には、紅蔘抽出物を添加してもＩＩＤ１６７７の生育（発育）に影響を及ぼすことなかった。 The MICs measured using IID1677 are shown in Table 3A below.
[Table 3A]

In addition, when no antibacterial agent was added, the growth (development) of IID1677 was not affected even if red ginseng extract was added.

なお、抗菌薬を添加しない場合には、紅蔘抽出物を添加してもＢＡＡ－１７１７の生育（発育）に影響を及ぼすことなかった。 The MICs measured using BAA-1717 are shown in Table 3B below.
[Table 3B]

In addition, when no antibacterial agent was added, the addition of red ginseng extract did not affect the growth (development) of BAA-1717.

なお、抗菌薬を添加しない場合には、紅蔘抽出物を添加してもＡＴＣＣ３３５９２の生育（発育）に影響を及ぼすことなかった。 The MICs measured using ATCC33592 are shown in Table 3C below.
[Table 3C]

In addition, in the case where no antibacterial agent was added, the addition of red ginseng extract did not affect the growth (development) of ATCC33592.

なお、抗菌薬を添加しない場合には、紅蔘抽出物を添加してもＡＴＣＣ４３３００の生育（発育）に影響を及ぼすことなかった。 The MICs measured using ATCC43300 are shown in Table 3D below.
[Table 3D]

In addition, when no antibacterial agent was added, the growth (development) of ATCC43300 was not affected even if red ginseng extract was added.

As shown in Tables 3A to 3D, when using β-lactam antibiotics or aminoglycoside antibiotics, the addition of red ginseng extract is different from the case where red ginseng extract is not added. MIC decreased in comparison. In particular, the MIC reduction rate of gentamicin and kanamycin, calculated from the above formula (1), is 75% or more in all evaluations using MRSA, which tends to be higher than the MIC reduction rate of other antibiotics. Ta. On the other hand, when macrolide antibiotics or tetracycline antibiotics were used, the MIC did not decrease even when red ginseng extract was added.

From the results of this evaluation described above, it was understood that the inhibitor of this embodiment was able to inhibit the resistance of MRSA to at least one of β-lactam antibiotics and aminoglycoside antibiotics. . In addition, it was understood that the inhibitor of the present embodiment was able to inhibit resistance to β-lactam antibiotics and/or aminoglycoside antibiotics, regardless of the type (strain) of the antibiotic-resistant bacteria. .

A formulation example of a soft drink containing a red ginseng extract according to the present embodiment is shown below.
(Prescription example)
Red ginseng extract used in evaluation 1 and evaluation 2 5.0g
Sucrose 3.0g
Fructose corn syrup 7.0g
Citric acid 0.1g
Remaining purified water (total amount is 100g)

A prescription example of the supplement (hard capsule) containing the red ginseng extract according to the present embodiment is shown below.
(Prescription example)
Red ginseng extract used in Evaluation 1 and Evaluation 2: 150.00mg/grain cellulose 97.50mg/grain starch 32.14mg/grain silicon dioxide 0.66mg/grain sucrose fatty acid ester 2.20mg/grain gelatin 63.00mg/grain grain

Claims (5)

An inhibitor of resistance of antimicrobial-resistant bacteria to the antimicrobial agent,
Contains red ginseng extract,
the antibacterial agent is at least one of a β-lactam antibacterial agent and an aminoglycoside antibacterial agent,
The red ginseng extract is a methanol extract of red ginseng extracted at 60°C or higher using 60 to 100% by volume of methanol, and independently exhibits an antibacterial effect against the antibacterial drug-resistant bacteria. do not have,
A resistance inhibitor characterized by: The resistance inhibitor according to claim 1 , wherein the antibacterial agent is gentamicin . The resistance inhibitor according to claim 1 or 2, wherein the antimicrobial drug-resistant bacterium is methicillin-resistant Staphylococcus aureus. A food and drink composition for inhibiting the resistance of antimicrobial-resistant bacteria to the antimicrobial agent,
Contains red ginseng extract,
the antibacterial agent is at least one of a β-lactam antibacterial agent and an aminoglycoside antibacterial agent,
The red ginseng extract is a methanol extract of red ginseng extracted at 60°C or higher using 60 to 100% by volume of methanol, and independently exhibits an antibacterial effect against the antibacterial drug-resistant bacteria. do not have,
Food and drink compositions for inhibiting tolerance. A resistance inhibition method for inhibiting the resistance of antimicrobial-resistant bacteria to the antimicrobial agent, the method comprising:
Including ingesting red ginseng extract;
the antibacterial agent is at least one of a β-lactam antibacterial agent and an aminoglycoside antibacterial agent,
The red ginseng extract is a methanol extract of red ginseng extracted at 60°C or higher using 60 to 100% by volume of methanol, and independently exhibits an antibacterial effect against the antibacterial drug-resistant bacteria. do not have,
Tolerance inhibition methods (excluding methods for treating humans) .